Related Experiment Video
Updated: Dec 31, 2025

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
Published on: February 16, 2024
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
Pamela Sue Becker1, Elizabeth A Griffiths2, Laura M Alwan3
1University of Washington/Seattle Cancer Care Alliance.
Abstract:
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Regulation of Hematopoietic Stem Cells
Hematopoiesis
Differentiation of Common Myeloid Progenitor Cells
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Multipotency of Hematopoietic Stem Cells

